|
March 14, 2023
|
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
|
|
March 8, 2023
|
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
|
|
March 7, 2023
|
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
|
|
February 7, 2023
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET
|
|
February 7, 2023
|
Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
|
|
January 31, 2023
|
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022
|
|
January 6, 2023
|
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference
|
|
January 3, 2023
|
Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
|